ライフサイエンスコーパス: adverse drug reaction

1 T pathway and herpesviruses in mediating the adverse drug reaction.

2 syndrome (aLQTS) is a serious unpredictable adverse drug reaction.

3 olvement of the fibrinolysis pathway in this adverse drug reaction.

4 h, disease remission or the occurrence of an adverse drug reaction.

5 ight into the pathophysiology of this severe adverse drug reaction.

6 by endocrine disrupting chemicals (EDCs) and adverse drug reactions.

7 marker studies advanced the understanding of adverse drug reactions.

8 ded details of 10 and 3 reports of suspected adverse drug reactions.

9 t in drug metabolism and have been linked to adverse drug reactions.

10 ase, resistance to pathogens and the risk of adverse drug reactions.

11 to pharmacotherapy whereas others experience adverse drug reactions.

12 orphisms that may underlie susceptibility to adverse drug reactions.

13 global analysis linking chemical features to adverse drug reactions.

14 ten inhibited by variable drug responses and adverse drug reactions.

15 e II binding compounds is essential to avoid adverse drug reactions.

16 ug pharmacokinetics, treatment efficacy, and adverse drug reactions.

17 an skin, a common target of inflammation and adverse drug reactions.

18 bating antibiotic resistance and unnecessary adverse drug reactions.

19 ficacy and reduce the number and severity of adverse drug reactions.

20 ommunity and hospital nurses in reporting of adverse drug reactions.

21 T cells involved in other serious cutaneous adverse drug reactions.

22 wn but cannot account for most idiosyncratic adverse drug reactions.

23 ehensive information on the risks of serious adverse drug reactions.

24 IV-1 RNA levels, CD4+ lymphocyte counts, and adverse drug reactions.

25 immune responses, and cause life-threatening adverse drug reactions.

26 ak international normalized ratio (INR), and adverse drug reactions.

27 reases, emerging research identifies various adverse drug reactions.

28 g-drug interactions account for up to 30% of adverse drug reactions.

29 xposed to serum from patients with cutaneous adverse drug reactions.

30 sex differences in therapeutic efficacy and adverse drug reactions.

31 tic markers or therapeutic targets for these adverse drug reactions.

32 (29.4%) reported all AEs, as opposed to only adverse drug reactions.

33 usion of diverse populations in the study of adverse drug reactions.

34 cations and are at higher risk of developing adverse drug reactions.

35 n, mortality, patient-reported outcomes, and adverse drug reactions.

36 uded time-to-hospitalization, mortality, and adverse drug reactions.

37 articaine injection in type and frequency of adverse drug reactions.

38 ublingual buprenorphine group experienced 21 adverse drug reactions.

39 ng a new approach to early identification of adverse drug reactions.

40 on were used to measure costs to treat these adverse drug reactions.

41 h Organization's global pharmacovigilance of adverse drug reactions.

42 actam therapy without increasing the risk of adverse drug reactions.

43 determine interindividual susceptibility to adverse drug reactions.

44 or example focussed on HLA associations with adverse drug reactions.

45 o repurpose existing drugs and identify rare adverse drug reactions.

46 the organs most commonly involved in serious adverse drug reactions.

47 ntial for serious drug-drug interactions and adverse drug reactions.

48 ovigilance system was put in place to detect adverse drug reactions.

49 alanced considering the increased tremor and adverse drug reactions.

50 et of covariates that influenced the rate of adverse drug reactions.

51 ajor, minor, and potentially iatrogenic; and adverse drug reactions.

52 rse event of grade 3 or higher, including 15 adverse drug reactions (11 hepatic events, all but 2 of

53 h need for additional drug therapy (31%) and adverse drug reactions (18%) being the most common probl

54 system on the Text Analysis Conference (TAC) Adverse Drug Reaction 2017 challenge test data set, cons

55 We recorded no serious adverse drug reactions; 28 adverse events, most commonly

56 ures; incidences of adverse events (AEs) and adverse drug reactions (33%) were low, no serious AEs we

57 ures; incidences of adverse events (AEs) and adverse drug reactions (33%) were low, no serious AEs we

58 < .001) without any increase in incidence of adverse drug reactions (4% vs 3%; P = .4).

59 and 1.7% for ST-Cefaz) and highest rates of adverse drug reactions (5.2% vs 4.6% for Hx-Cefaz and 4.

60 Ritonavir was associated with adverse drug reactions about twice as frequently as indi

61 finition and clinical evaluation for a novel adverse drug reaction (ADR) based on a series of recentl

62 Report of a prior NSAID-induced adverse drug reaction (ADR) may preclude use of first-li

63 dy aimed to explore the global observational adverse drug reaction (ADR) profiles of the HDACIs: vori

64 of the Med Safety app in improving suspected adverse drug reaction (ADR) reporting by health-care wor

65 ISDs owing to clinical efficacy, inefficacy, adverse drug reaction (ADR), and other medical causes.

66 rage risk of short- (9%) and long-term (30%) adverse drug reaction (ADR); (2) an 80-year-old woman wi

67 Adverse drug reactions (ADRs) accounted for the majority

68 Two spontaneously reported serious adverse drug reactions (ADRs) and 32 spontaneously repor

69 There is some evidence that adverse drug reactions (ADRs) and hypersensitivity react

70 rhinitis score (TCRS), adverse events (AEs), adverse drug reactions (ADRs) and immunological response

71 of studies identifying HLA associations with adverse drug reactions (ADRs) and one for the examinatio

72 Adverse drug reactions (ADRs) are a central consideratio

73 Adverse drug reactions (ADRs) are a common cause of attr

74 Adverse drug reactions (ADRs) are a relatively common ca

75 Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized sou

76 Adverse drug reactions (ADRs) are commonplace and occur

77 Adverse Drug Reactions (ADRs) are of great public health

78 Idiosyncratic adverse drug reactions (ADRs) are one of the most common

79 aim of the study was to investigate whether adverse drug reactions (ADRs) during immunotherapy with

80 Adverse drug reactions (ADRs) harm patients and are cost

81 The presence of adverse drug reactions (ADRs) is an ongoing public healt

82 The spectrum of vaccine-related adverse drug reactions (ADRs) is extremely broad, and th

83 re an important tool for predicting clinical adverse drug reactions (ADRs) of investigational drugs.

84 o estimate the impact of self-reported NSAID adverse drug reactions (ADRs) on risk of OUD, adjusting

85 Adverse drug reactions (ADRs) pose critical public healt

86 Reliable prediction and prevention of adverse drug reactions (ADRs) remains a key challenge in

87 al interest (AESIs), serious AEs (SAEs), and adverse drug reactions (ADRs) reported during postinject

88 Adverse drug reactions (ADRs) requiring closer monitorin

89 rugs may be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, bu

90 total, the one-strength regimen caused more adverse drug reactions (ADRs) than the Standard regimen

91 , spontaneous reports do not reliably detect adverse drug reactions (ADRs) that occur widely separate

92 nts, and pharmaceutical companies can report adverse drug reactions (ADRs) to pharmacovigilance datab

93 Adverse drug reactions (ADRs) to tuberculosis (TB) medic

94 to identify whether phenotypes indicative of adverse drug reactions (ADRs) were enriched in drug-expo

95 intervention and 0.1% (23) death related to adverse drug reactions (ADRs) were reported.

96 e psoriasis (PSO), and nonpustular cutaneous adverse drug reactions (ADRs), as well as from healthy s

97 armacy in older adults increases the risk of adverse drug reactions (ADRs), but studying this relatio

98 onvulsant carbamazepine 1 is associated with adverse drug reactions (ADRs), including hepatotoxicity;

99 A total of 14% of patients experienced minor adverse drug reactions (ADRs), of which 2 cases demonstr

100 2 (62.5%) participants experienced 1 or more adverse drug reactions (ADRs), of which 38 (10.5%) and 9

101 Use of medication can cause adverse drug reactions (ADRs), unwanted or unexpected ev

102 ncluded the incidence and timing of onset of adverse drug reactions (ADRs).

103 test their association with ACEi-associated adverse drug reactions (ADRs).

104 science that monitors, detects, and prevents adverse drug reactions (ADRs).

105 ics, and these are associated with a risk of adverse drug reactions (ADRs).

106 duct were classified by the investigators as adverse drug reactions (ADRs).

107 rgy to cephalosporin or incidence of serious adverse drug reactions (ADRs).

108 ontinue thiopurine therapy because of severe adverse drug reactions (ADRs); leukopenia is one of the

109 lth Organization's (WHO) global database for adverse drug reactions, ADRs, VigiAccess.

110 to clarify key terms, such as adverse event, adverse drug reaction, adverse drug event, medication er

111 d serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) fo

112 rmining patient susceptibility to developing adverse drug reactions, although the underlying mechanis

113 lar mechanism of undesirable drug effects or adverse drug reactions among those compounds, we examine

114 iate stage) between the identification of an adverse drug reaction and the subsequent onset of drug-i

115 Collection of adverse drug reactions and anticancer activity attributa

116 DDIs are an important cause of adverse drug reactions and exact a large toll on the hea

117 , we have added evaluation of post-marketing adverse drug reactions and new curated information on ta

118 eriments, a failure to routinely incorporate adverse drug reactions and serum metabolite monitoring i

119 The occurrence of adverse drug reactions and somnolence were observed in 1

120 ing antibiotic prophylaxis, and risk of both adverse drug reactions and the potential for promoting a

121 Thiopurine-related adverse drug reactions and thiopurine failure are freque

122 reduced the incidence of clinically relevant adverse drug reactions and was feasible across diverse E

123 ory, comorbidities, drug interactions, prior adverse drug reactions, and DST results.

124 ams was used to assess treatment completion, adverse drug reactions, and factors associated with trea

125 pital length of stay, additional procedures, adverse drug reactions, and hospital-acquired infections

126 promiscuous drugs, polypharmacology-related adverse drug reactions, and multi-drug therapies, especi

127 Adverse drug reactions are a frequent culprit.

128 Adverse drug reactions are a significant cause of morbid

129 Adverse drug reactions are a significant public health p

130 ever, treatment failure due to resistance or adverse drug reactions are common, asking for new therap

131 Although many adverse drug reactions are considered nonpreventable, re

132 Immune-mediated type IV adverse drug reactions are idiosyncratic in nature, gene

133 Schemes for spontaneous reporting of adverse drug reactions are important to post-marketing s

134 Idiosyncratic adverse drug reactions are unpredictable, dose-independe

135 ed approach to trimethoprim-sulfamethoxazole adverse drug reaction assessment and rechallenge to opti

136 Three adverse drug reaction assessment instruments were used t

137 estigates differences by sex in reporting of adverse drug reactions associated with angiotensin-conve

138 objective was to determine the prevalence of adverse drug reactions associated with off-label use and

139 e, indicating that doctors should report all adverse drug reactions associated with them to the Commi

140 ned as discontinuation of treatment owing to adverse drug reactions) associated with amitriptyline (o

141 To improve the detection of adverse drug reactions at our hospital, we utilized elec

142 e phenotypes can range from life-threatening adverse drugs reactions at one end of the spectrum to eq

143 is was not observed in less severe cutaneous adverse drug reactions, autoimmune diseases, or neutroph

144 or potential avoidability with the Liverpool adverse drug reactions avoidability tool (LAAT) by the s

145 with acute adenovirus infections or systemic adverse drug reactions, but levels in patients with KD w

146 Serious cutaneous adverse drug reactions (cADRs) are potentially life-thre

147 to antiseizure medication-induced cutaneous adverse drug reactions (cADRs), such as human leucocyte

148 s seldom studied in other types of cutaneous adverse drug reactions (cADRs).

149 A total of 37,848 dupilumab adverse drug reaction cases were reported, with skin, ey

150 in-induced thrombocytopenia, a prothrombotic adverse drug reaction caused by immunoglobulin G directe

151 auses one in three market withdrawals due to adverse drug reactions, causing preventable human suffer

152 sis (TEN) are life-threatening mucocutaneous adverse drug reactions characterized by massive epiderma

153 al necrolysis (SJS/TEN) are severe cutaneous adverse drug reactions characterized by widespread kerat

154 a higher risk of presenting with a cutaneous adverse drug reaction compared with non-sulfonamides and

155 verse events (AEs), serious AEs, and serious adverse drug reactions compared with control chemotherap

156 to identify and characterize cardiovascular adverse drug reactions (CV-ADR) associated with ibrutini

157 se reports are derived mainly from voluntary adverse drug reaction databases, they might be prone to

158 lasma drug levels, which are associated with adverse drug reactions, delayed treatment response, and

159 istered and the number of harmful and severe adverse drug reactions did not differ for medications us

160 Although adverse drug reactions do not occur more frequently with

161 s (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions documented either at baseline or

162 Tremor rates and adverse drug reactions favoured the placebo group.

163 the evidence for a genetic predisposition to adverse drug reactions, focusing on gene variants produc

164 The number of adverse drug reactions for medications administered and

165 ded demographics, costs, outcomes (including adverse drug reactions, functional status, ventilator ti

166 vate platelets, leading to the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (

167 e Abs are associated with an immune-mediated adverse drug reaction, heparin-induced thrombocytopenia.

168 Idiosyncratic adverse drug reactions (IADRs) encompass a diverse group

169 f reactive metabolites in many idiosyncratic adverse drug reactions (IADRs).

170 previously established profile, with no new adverse drug reactions identified.

171 timize antipsychotic treatment by preventing adverse drug reactions, improving treatment efficacy or

172 nsight into the molecular mechanisms of this adverse drug reaction in adult patients with germ cell t

173 a is a rare but potentially life-threatening adverse drug reaction in patients receiving angiotensin-

174 vs 23/27; P = .0001), with no recurrence of adverse drug reactions in 74%.

175 use as a risk factor for the development of adverse drug reactions in an adult ICU population.

176 present a novel method to better investigate adverse drug reactions in chemical space.

177 Adverse drug reactions in children are an important publ

178 drug testing does not predict some forms of adverse drug reactions in humans.

179 ld be helpful in identification of potential adverse drug reactions in mono as well as combination th

180 urveillance techniques to reduce the risk of adverse drug reactions in patients receiving warfarin.

181 extrapolated to calculate incidence rates of adverse drug reactions in the community from spontaneous

182 control group) or amiodarone side effects or adverse drug reactions (in the rhythm-control group).

183 c transporter genes previously implicated in adverse drug reactions including simvastatin-induced myo

184 d therapy with PGx targeted drugs and/or for adverse drug reactions, including lack of therapeutic be

185 could have identified several DDI-associated adverse drug reactions, including severe and life-threat

186 Adverse drug reactions, including severe patient bleedin

187 potentially involved in dupilumab-associated adverse drug reactions, including the fibroblast GF rece

188 It was found that the rate of adverse drug reactions increases by 8% for every one add

189 ntrol a variety of manifestations, including adverse drug reactions, inflammatory conditions, bacteri

190 s were the number of medications, nonserious adverse drug reactions, injurious falls, quality of life

191 Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction involving extensive keratinocyte d

192 Potential hepatic adverse drug reaction is a safety concern associated wit

193 ng the unintended 'off-targets' that predict adverse drug reactions is daunting by empirical methods

194 their unintended 'off-targets' that predict adverse drug reactions, is a daunting task by experiment

195 tic agent, yet its use is limited by several adverse drug reactions, known as cisplatin-induced toxic

196 ne-induced cardiotoxicity (ACT) is a serious adverse drug reaction limiting anthracycline use and cau

197 he depot buprenorphine group experienced 117 adverse drug reactions, mainly injection site reactions

198 One risk factor for adverse drug reactions may be age.

199 n concludes that death and disability due to adverse drug reactions may be prevented if mechanistic i

200 ion in renal transplant recipients, reported adverse drug reactions may limit use and increase relian

201 Adverse drug reactions, morning peak flow (mPEF) and ast

202 an explanation for HLA-linked idiosyncratic adverse drug reactions, namely that drugs can alter the

203 rget of a given drug, creating a drug-target-adverse drug reaction network.

204 creased parathyroid hormone, the most common adverse drug reactions (No./total No.) were nausea (iron

205 e index drug (n=1558), a clinically relevant adverse drug reaction occurred in 152 (21.0%) of 725 pat

206 owever, no life-threatening severe cutaneous adverse drug reactions occurred, and the decision for dr

207 ulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction occurring in up to 1% of treated i

208 Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction occurring in up to 5% of patients

209 )Ga-DOTA-MGS5 was well tolerated, with minor adverse drug reactions occurring only in 3 patients.

210 a (HIT) is a relatively common prothrombotic adverse drug reaction of unusual pathogenesis that featu

211 d provide biological insights into potential adverse drug reactions of co-prescribed drugs.

212 By integrating data sources about adverse drug reactions of drugs with an established chem

213 regarding the lack of therapeutic benefit or adverse drug reactions of PGx targeted drugs.

214 Drug-induced taste disturbance is a common adverse drug reaction often triggered by drug secretion

215 tion may enhance drug metabolism (leading to adverse drug reactions) or inhibit inflammation.

216 ference, 3.4 pp [95% CI, -2.0 to 8.8 pp]) or adverse drug reactions (oral, 2.7%; intramuscular, 1.1%;

217 reactions (P = .059); 78.3% and 45.2% had 1 adverse drug reactions (P < .001); and post-treatment QF

218 ician- and patient-reported clinical events, adverse drug reactions, patient quality of life (EQ-5D-5

219 Secondary outcomes included adverse drug reaction, PICC line complication, and a com

220 ptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE), a multicenter, control

221 drug acquisition cost, and costs of treating adverse drug reactions probably or possibly related to s

222 ractions involving AAD can result in serious adverse drug reactions ranging from arrhythmia recurrenc

223 Three subjects reported mild adverse drug reactions related to FCM; two of these were

224 Our institutional adverse drug reaction reporting program was used to iden

225 VigiBase, a database of adverse drug reaction reports from over 140 countries, c

226 were used to determine the probability of an adverse drug reaction resulting from drug therapy.

227 n (VHA) data to estimate the costs of severe adverse drug reactions resulting in or contributing to h

228 centrations during hypothermia and increased adverse drug reaction risk complicates concurrent pharma

229 iomarkers with the strongest associations to adverse drug reaction risk in the intensive care unit ar

230 ot occur more frequently with off-label use, adverse drug reaction risk increases with each additiona

231 in the other outcomes, including nonserious adverse drug reactions (RR, 0.92 [95% CI, 0.58-1.46]), i

232 re subsequently discovered to have suspected adverse drug reactions (SADRs).

233 Adverse drug reaction screens in a kidney panel revealed

234 While recent advances in pharmacogenetics of adverse drug reactions show promise, the small size of t

235 s recent literature documenting the risk for adverse drug reactions specific to bleeding and/or clott

236 We included 18 of 333 adverse drug reaction studies and 22 of 61 variant allel

237 ween mitochondrial DNA (mtDNA) variation and adverse drug reactions such as idiosyncratic drug-induce

238 Tuberculosis (TB) treatment-related adverse drug reactions (TB-ADRs) can negatively affect a

239 reciation of the role that genetics plays in adverse drug reactions that are either predictable exten

240 objective of pharmacovigilance is to detect adverse drug reactions that are unknown or novel in term

241 ylactoid reactions are common clinical acute adverse drug reactions that can exacerbate a patient's c

242 The role of the adaptive immune system in adverse drug reactions that target the liver has not bee

243 rld Health Organization's classification for adverse drug reactions, the association between bortezom

244 In an effort to prevent adverse drug reactions, the FDA mandates the evaluation

245 ere assessed daily for the development of an adverse drug reaction through active surveillance.

246 tcome was any clinical event described as an adverse drug reaction to one or more drugs.

247 potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin or, less

248 anges in cholesterol levels that could cause adverse drug reactions to cholesterol-lowering drugs suc

249 om the World Health Organization database of adverse drug reactions to examine the association of ant

250 allele that may be associated with the rare adverse drug reaction torsades de pointes.

251 s to deprescribe include present or expected adverse drug reactions, unnecessary polypharmacy, and th

252 alues to find associations between drugs and adverse drug reactions using disproportionate Bayesian-r

253 The growing concern over potentially serious adverse drug reactions warrants an evaluation of post ma

254 a grade 2 clinical and/or grade 3 laboratory adverse drug reaction was reported, leading to delayed t

255 The incidence of adverse drug reactions was 9.4% (5 of 53), and all of th

256 Severity and harm of the adverse drug reaction were also assessed.

257 Rates of adverse drug reaction were low (<4% in both groups) but

258 on resource utilization associated with each adverse drug reaction were used to measure costs to trea

259 M/MF and SSG/PM efficacies were similar, and adverse drug reactions were as expected given the drugs

260 One hundred and sixteen adverse drug reactions were categorized dichotomously (F

261 The incidence and severity of other adverse drug reactions were comparable between the 2 gro

262 Unexpected adverse drug reactions were found in the "intestinal obs

263 Adverse drug reactions were less common in the TMP-SMX p

264 Discontinuations due to adverse drug reactions were lowest for TDF+FTC+RAL (1.9%

265 reactions was 9.4% (5 of 53), and all of the adverse drug reactions were mild.

266 The most common adverse drug reactions were ocular side effects, includi

267 Three adverse drug reactions were regarded as both serious and

268 Adverse drug reactions were reported by 1174 (35.7%) pat

269 Adverse drug reactions were reported by 30.6% of patient

270 53% (27) of 51 events classified as serious adverse drug reactions were reported.

271 No serious adverse drug reactions were reported.

272 severe, but no suspected unexpected serious adverse drug reactions were seen.

273 8 drug pairs (305 associated with at least 1 adverse drug reaction) were reported.

274 been associated with serious T cell-mediated adverse drug reactions, which has led to preventive scre

275 taphylococcus aureus sinusitis, and multiple adverse drug reactions whose T cells were unable to prod

276 ion of genetic variants associated with this adverse drug reaction will further our mechanistic under

277 Less than 1% of women reported adverse drug reactions, with no increase in HIV-positive

278 me was the occurrence of clinically relevant adverse drug reactions within the 12-week follow-up peri